Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inactive ubiquitin carboxyl-terminal hydrolase MINDY-4B (MINDY4B) is a member of the MINDY family of putative deubiquitinase enzymes, predicted to specifically target K48-linked ubiquitin chains for deubiquitination, although it is characterized as "inactive" and its enzymatic activity has not been experimentally demonstrated[1][2][4][7][8]. MINDY4B is a protein-coding gene with tissue expression observed in various human tissues, but its physiological roles and relevance as a therapeutic target are currently unclear[3]. Diseases reported to be associated with this gene include autosomal dominant deafness and glioma susceptibility, but direct mechanistic links require further investigation[1]. There are no known approved drugs or established biomarkers targeting MINDY4B, and it is not presently considered a validated therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inactive ubiquitin carboxyl-terminal hydrolase MINDY-4B (MINDY4B).